Key Takeaway: The article discusses a novel reverse immunology platform that utilizes machine learning to reconstruct human antibodies from tertiary lymphoid structures (TLS) found in patient samples. This approach aims to leverage immune transcriptomics to develop antibodies directly from diseased tissues, particularly those showing exceptional outcomes in various diseases. The technology holds promise for advancements in treating cancer and other conditions.
Price reaction · baseline $4.74 (2024-04-30 close) · hit pre-market · 1 other ABSI headline(s) in the window, move may be shared
day 0 close
+9.5%
day 1
+5.1%
day 3 · peak
+9.9%
Market Sentiment Analysis
POSITIVE FACTORS
Innovative use of machine learning for antibody development.
Focus on patient samples with exceptional outcomes.
Potential applications in cancer, auto-immune, and infectious diseases.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Cash runway
~12 mo
Medium dilution risk
Lead asset
ABS-201 Single Dose
Phase 1 · Androgenetic Alopecia (AGA)
Full Press Release Details
Human anti-MAGEA Antibodies Derived from Tertiary Lymphoid Structures of Cancer Patients
We have developed a reverse immunology platform that relies on machine learning-guided reconstruction of antibodies from diseased tissue sources, such as tertiary lymphoid structures (TLS) derived from patient samples with exceptional outcomes in cancer, auto-immune, and infectious diseases. Using immune transcriptomics and artificial intelligence, our reverse immunology pipeline can reconstruct fully human antibodies directly from patient samples by combining heavy and light chains of antibodies isolated from TLS within affected tissue.
Frequently Asked Questions
What is the reverse immunology platform?
It is a platform that uses machine learning to reconstruct antibodies from diseased tissue.
What are tertiary lymphoid structures?
TLS are immune structures found in tissues affected by diseases, including cancer.
How are antibodies reconstructed?
Antibodies are reconstructed by combining heavy and light chains from TLS in patient samples.
What diseases can this platform potentially address?
It may be applicable to cancer, auto-immune, and infectious diseases.